Clean Science and Technology reported a 3% year-on-year decline in operating profit for Q1 FY27, with margins shrinking to 35.9%. The company faces ongoing challenges from global economic uncertainty and logistics disruptions, though planned capacity expansions in its performance chemicals segment remain a key focus for future growth.
Clean Science and Technology has reported a challenging start to the 2027 fiscal year, reflecting the wider difficulties currently impacting the Indian specialty chemicals sector. In its latest quarterly update, the company recorded an EBITDA of INR 964 million, a 3% decrease compared to the same period last year. Profitability metrics also faced pressure, with the EBITDA margin narrowing to 35.9% from 41.1% in Q1 FY26, as gross margins slipped to 60.9%.
Impact of Global Supply and Macro Factors
The company’s performance was largely influenced by external pressures, including global macroeconomic instability and geopolitical tensions that have weighed on product pricing across the industry. Furthermore, supply chain hurdles, specifically a lack of available shipping vessels, caused delays in export shipments. These logistics constraints created temporary bottlenecks, impacting the company's ability to maintain its usual delivery schedules during the quarter.
Expansion Plans and Future Growth
Despite the recent dip in profitability, the company continues to invest in long-term growth through capacity expansion. Investors are looking toward the planned ramp-up of its performance chemical 1 plant and the upcoming commercialization of its performance chemical 2 unit, which is expected by the third quarter of FY27. Additionally, the company is focusing on scaling up its Hindered Amine Light Stabilizers (HALs) business and improving internal process efficiencies to support better margins over time.
Valuation and Market Context
Brokerage firm Motilal Oswal has maintained a 'Neutral' rating on the stock, citing these operational headwinds. The firm has set a target price of INR 790, valuing the stock at 25 times its estimated earnings per share for FY28. While the brokerage maintains its earnings estimates for the coming two years, the immediate focus remains on how effectively the company can navigate current pricing pressures and execute its pending capacity additions. For shareholders, the key monitorables moving forward will be the successful commissioning of the performance chemical 2 plant and any signs of recovery in global demand which could help restore profit margins to historical levels.